All News
Filter News
Found 237 articles
-
How a US Recession Could Affect Biopharma
12/22/2022
U.S. recession will inevitably make many biopharma companies change course. However, it could cause some biotechs to change for the better. -
Clinical trial platform provider encapsia welcomes new COO
12/21/2022
Clinical trial management solutions provider, encapsia, has announced the appointment of Francis Destin as its new Chief Operating Officer.
-
Cybin Highlights 2022 Accomplishments and Milestones
12/20/2022
Cybin Inc. is pleased to provide a year-end summary of its key milestone accomplishments in 2022.
-
CPC's MicroCNX Series Connectors Receive Top Biopharma Industry Honor
12/7/2022
CPC (Colder Products Company), part of Dover (NYSE: DOV) and a leading manufacturer of connection technologies used in biopharmaceutical processing, today announced that its MicroCNX® Series Connectors were named a 2022 Pharma Innovation Award winner.
-
Mindset Pharma to Participate in Upcoming Conferences in December 2022
12/6/2022
Mindset Pharma Inc. today announced that James Lanthier, CEO of Mindset, and Joseph Araujo, CSO, will participate in two upcoming conferences.
-
Moving Past Animal Models with Better Data for Drug Discovery
11/24/2022
With the FDA Modernization Act's passage earlier this year, drug developers have the opportunity to forgo animal models in preclinical development for the first time in history.
-
BioSpace spoke with Annick Deschoolmeester, Head of Human Resources at Pharvaris, about some of the ways she's noticed small companies differ from large ones.
-
Mindset Pharma and PharmAla Enter into Exclusive Sales Agreement for the Sale and Distribution of Pharmaceutical Grade Psilocybin
11/16/2022
Mindset Pharma Inc. and PharmAla Biotech Holdings Inc. today announced that they have entered into an exclusive sales agreement.
-
Find out everything you need to know about research and development, including the skills it requires and what you should do if you’re ready to make the transition into R&D.
-
Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug CandidateTolerability of MSP-1014 May Be Superior to Psilocybin
11/14/2022
Mindset Pharma Inc. today announced data from preclinical studies comparing its novel prodrug of psilocin, MSP-1014.
-
Cybin Obtains Exclusive License to a Novel Catalog of Psychedelic-Based Compounds
9/27/2022
Cybin Inc. has entered into an agreement with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset”) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from Mindset (the “Agreement”).
-
Mindset Pharma Provides Strategic Intellectual Property License to Cybin
9/27/2022
Mindset Pharma Inc. today announced an exclusive licensing agreement for Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) to acquire intellectual property rights for a subset of Mindset’s preclinical compounds (the “Agreement”).
-
Novartis outlined how its transformation to a pure-play innovative medicines company is nearly completed during a "Meet the Management" event in Switzerland.
-
Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy
9/20/2022
Optimind Pharma Corp. (CSE: OMND) ("Optimind" or the "Company") an emerging provider of psychedelic therapies focused on improving the everyday quality of life for individuals who suffer from PTSD, anxiety, depression, and other mental illnesses or disabilities announces today its acquisition of MindSetting Institute, a leader in psychedelic enhanced therapy training and educational programming.
-
Mindset Pharma Receives Scientific Advice from UK Regulator Facilitating Advancement of Phase 1 First-In-Human Clinical Trial Plan for Its Lead Clinical Candidate, MSP-1014
9/14/2022
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today announced that the Company has received Scientific Advice from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) on a range of points to finalize its Phase 1 first-in-human clinical trial plan evaluating its lead psychedelic drug candidate MSP-1014 for the treatment of Major Depressive Disorders (MDD) .
-
Mindset Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
8/30/2022
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company"), today announced that James Lanthier, CEO, and Joseph Araujo, CSO of Mindset, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.
-
Tessera Therapeutics Expands Leadership and Board
8/24/2022
Tessera Therapeutics, the biotechnology company pioneering GENE WRITING™ technology, today announced the appointment of Anne-Virginie Eggimann, M.Sc. as Chief Regulatory Officer (CRO) responsible for leading U.S. and global regulatory science and program.
-
Sanofi, Certara, Pfizer and Thermo Fisher are facing hiring challenges head-on with a common strategy: upskilling programs. They use these programs to fill open roles while training and retaining existing talent.
-
OSE Immunotherapeutics Appoints Alexis Vandier as Chief Executive Officer
7/13/2022
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective immediately.
-
BioSpace caught up with Roland and Ben Buelow of Ancora, and Lightspeed Venture Partners' Galym Imanbayev to talk about the AstraZeneca deal and the company's unique business model.